PAIN THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM HUMAN ABUSE POTENTIAL STUDY WITH REMOXY
REMOXY Meets Both Primary Endpoints with Statistical Significance (p < 0.0001)
AUSTIN, Texas, May 12, 2015 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc., (Nasdaq:PTIE) today announced top-line results of an FDA Category 3 Human Abuse Potential Study with REMOXY Extended-Release Capsules CII, its lead drug candidate that is specifically designed to discourage certain common methods of drug tampering and misuse. This study demonstrated with statistical significance (p < 0.0001) that both intact and chewed REMOXY were less "liked" than immediate-release oxycodone on the two primary endpoints, Drug Liking and Drug High. The Abuse Potential study was conducted in non-dependent, recreational opioid users, as recommended by FDA guidelines.
"We believe today's results demonstrate abuse-deterrent properties of the REMOXY formulation against a common, and often lethal, form of oral drug abuse," said Nadav Friedmann, PhD, MD., Pain Therapeutics' Chief Medical Officer.
Study Design
Pain Therapeutics' former corporate partner for REMOXY had sole responsibility for this FDA Category 3 Human Abuse Potential Study with REMOXY. This study was conducted in accordance with draft FDA Guidance to Industry on Abuse Deterrent Opioids and interactions between the study sponsor and FDA. The study was randomized, double-blind, placebo and active controlled, using a 4-way crossover design in healthy, non-dependent recreational opioid users. Nearly 60 subjects completed this study, with an average age of 27 years. The study's primary objective was to measure the abuse potential of chewed and intact 40mg REMOXY compared to 40mg immediate-release (IR) oxycodone when taken orally. Study subjects were instructed to chew REMOXY capsules vigorously for up to 5 minutes, but none were able to do so in light of REMOXY's high viscosity, texture or taste. Pharmacodynamic measures of the primary endpoints, Drug Liking and Drug High, included use of a standard 0-100 point Visual Analogue Scale (VAS) in the initial two hours post-dose (AUC02h), as recommended by FDA to assess a formulation's abuse potential. The sponsor generated study tables for this Abuse Potential Study in December 2014. Pain Therapeutics has not performed an independent analysis of study results.
Top-line Study Results
Clinical and statistical highlights include:
On the co-primary endpoint of Drug Liking, scores were significantly lower for intact REMOXY (p < 0.0001) and for chewed REMOXY (p < 0.0001) compared to IR oxycodone.
On the co-primary endpoint of Drug High, scores were significantly lower for intact REMOXY (p < 0.0001) and for chewed REMOXY (p < 0.0001) compared to IR oxycodone.
On the secondary endpoint of Good Drug Effects, scores were significantly lower for intact REMOXY (p < 0.0001) and for chewed REMOXY (p < 0.0001) compared to IR oxycodone.
On the secondary endpoint of Bad Drug Effects, scores were significantly higher for intact REMOXY (p < 0.0001) and for chewed REMOXY (p < 0.0079) compared to IR oxycodone.
On the secondary endpoint of Pupil Constriction, scores were significantly lower for intact REMOXY (p < 0.0001) and for chewed REMOXY (p < 0.0001) compared to IR oxycodone.
On the secondary endpoint of Nausea, scores were significantly lower for intact REMOXY (p < 0.0001) and for chewed REMOXY (p < 0.0143) compared to IR oxycodone.
On the secondary endpoint of Feel Sick, scores were significantly lower for intact REMOXY (p < 0.0002) and for chewed REMOXY (p < 0.039) compared to IR oxycodone.
"We believe results of today's study speak to the clinical and commercial potential of REMOXY," said Remi Barbier, President & CEO of Pain Therapeutics. "REMOXY's high viscosity is intended to deter injection and snorting. We believe this feature, coupled to today's data on oral abuse, contributes to an overall assessment of abuse potential that supports a label-claim for REMOXY."
http://www.biotechnologyevents.com/node/6987
Recent DRRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 04:53:49 PM
- DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference • PR Newswire (US) • 09/04/2024 08:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/26/2024 04:15:12 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/14/2024 09:01:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:15:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/12/2024 08:10:03 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/12/2024 08:05:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 05:03:36 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/02/2024 08:30:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:35:08 PM
- DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis • PR Newswire (US) • 05/21/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:03:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:17:26 PM
- DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update • PR Newswire (US) • 05/13/2024 08:05:00 PM
- DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update • PR Newswire (US) • 05/07/2024 08:30:00 PM
- DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis • PR Newswire (US) • 04/30/2024 11:00:00 AM
- DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • PR Newswire (US) • 03/27/2024 08:01:00 PM
- DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update • PR Newswire (US) • 03/20/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 04:37:57 PM
- DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada • PR Newswire (US) • 03/04/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:16:39 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM